Efficacy of sitafloxacin as third-line eradication treatment of Helicobacter pylori

Efficacy of sitafloxacin as third-line eradication treatment of Helicobacter pylori - Helicobacter pylori rescue therapy by sitafloxacin

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004778

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection

Interventions

Eradication treatment by rabeprazole 10mg q.i.d. and amoxicillin 500mg q.i.d. and sitafloxacin 100mg b.i.d. for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: H. pylori positive patient after first-line and second-line eradication treatment

Exclusion criteria

Exclusion criteria: 1. Patient with severe heart failure, renal failure or infection. 2. Patients with allergy for rabeprazole, amoxicillin or sitafloxacin. 3. Pregnant patient.

Design outcomes

Primary

Measure	Time frame
Eradication rate	—

Countries

Japan

Contacts

Public ContactToshihiro Nishizawa

National Organization Tokyo medical center Gastroenterology

03-3411-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026